当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Recent Advances in the Chemotherapy of Breast Cancer

Navya V, Pavan S, Aravinda Swami P

In the course of recent decades, the fundamental treatment of bosom tumor (early and progressed) has changed significantly. Chemoprevention is a recently introduced and quickly developing region of oncology that is distinguishing agents with a potentially preventive part in malignancy. For as far back as 40– 50 years, and since the disclosure and further restorative utilization of Tamoxifen, a particular estrogen receptor modulator, bosom disease treatment has turned to the advancement and accomplishment of custom fitted restorative treatment. Much still should be done in enhancing results, and particularly for the individuals who have propelled breast cancer, a testing zone for medicinal oncologists. Continuous global clinical trials are right now assessing new helpful methodologies and distinguishing particular natural subsets that could decide a patient's capacity to react to specific chemotherapeutic drugs.